Free Trial
NASDAQ:ONC

BeOne Medicines 5/7/2025 Earnings Report

BeOne Medicines logo
$297.49 +0.35 (+0.12%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$297.23 -0.26 (-0.09%)
As of 05/5/2026 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines EPS Results

Actual EPS
$1.22
Consensus EPS
-$0.71
Beat/Miss
Beat by +$1.93
One Year Ago EPS
N/A

BeOne Medicines Revenue Results

Actual Revenue
$1.12 billion
Expected Revenue
$1.12 billion
Beat/Miss
Missed by -$7.30 million
YoY Revenue Growth
N/A

BeOne Medicines Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

BeOne Medicines' Q2 2026 earnings is scheduled for Wednesday, May 6, 2026

Conference Call Resources

BeOne Medicines Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More BeOne Medicines Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BeOne Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeOne Medicines and other key companies, straight to your email.

About BeOne Medicines

BeOne Medicines (NASDAQ:ONC) Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

View BeOne Medicines Profile